Zadie Davis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zadie Davis has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- David G. Oscier
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK
2 shared publications - Achilles Anagnostopoulos
George Papanicolaou General Hospital, Thessaloniki, Greece
1 shared publication - Amy Christian
Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK
1 shared publication Andreas Agathangelidis
Division of Molecular Oncology Department of Onco‐Haematolgy Istituto Scientfico San Raffaele Fondazione Centro San Raffaele Università Vita‐Salute San Raffaele Milan Italy
1 shared publicationAnne Gardiner
Department of Molecular Pathology, Royal Bournemouth Hospital, Sutton, UK
1 shared publication- Anne Gardiner
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK
1 shared publication
Latest Publications
- Open Access
- 9 April 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (4) , E73-E76
Importance of sequential analysis of TP53 variation in patients with Waldenström Macroglobulinaemia
- 9 April 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (4) , E73-E76
Open AccessImportance of sequential analysis of TP53 variation in patients with Waldenström Macroglobulinaemia
- 5 February 2016
- Published by Wiley in British Journal of Haematology
- Vol. 173 (1) , 127-136
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity
Summary: IGHV gene mutational status has prognostic significance in chronic lymphocytic leukaemia (CLL) but the percentage of mutations that correlates best with clinical outcome remains controversial. We initially studied 558 patients from diagnosis and found significant differences in median time to first treatment (TTFT) among Stage A patients and in overall survival (OS) for the whole cohort, between cases with IGHV3‐21 Stereotype Subset #2 were excluded. A significant difference in progression‐free survival (PFS) and OS between those with IGHV genes defined as <98% identity to germline.
- 5 February 2016
- Published by Wiley in British Journal of Haematology
- Vol. 173 (1) , 127-136
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity
Summary: IGHV gene mutational status has prognostic significance in chronic lymphocytic leukaemia (CLL) but the percentage of mutations that correlates best with clinical outcome remains controversial. We initially studied 558 patients from diagnosis and found significant differences in median time to first treatment (TTFT) among Stage A patients and in overall survival (OS) for the whole cohort, between cases with IGHV3‐21 Stereotype Subset #2 were excluded. A significant difference in progression‐free survival (PFS) and OS between those with IGHV genes defined as <98% identity to germline.
- 12 April 2014
- Published by Wiley in British Journal of Haematology
- Vol. 166 (4) , 621-625
The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors
- 12 April 2014
- Published by Wiley in British Journal of Haematology
- Vol. 166 (4) , 621-625
The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors
- Open Access
- 5 December 2007
- Published by Wiley in British Journal of Haematology
- Vol. 140 (3) , 320-323
Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia – long-term follow up of patients with different percentages of mutations
- 5 December 2007
- Published by Wiley in British Journal of Haematology
- Vol. 140 (3) , 320-323
Open AccessDetermination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia – long-term follow up of patients with different percentages of mutations